The Pharma Data

JULY 29, 2021

Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Biosimilars marketed in the U.S. for the treatment of diabetes.

Biosimilars 52

Biosimilars Production FDA Approval FDA 52

Drug Channels

NOVEMBER 4, 2024

Here on Drug Channels , we have long highlighted the boom in provider-administered biosimilars. In contrast to the pharmacy market, adoption of these biosimilars is growing, prices are dropping, and formulary barriers continue to fall. As we demonstrate, health plans pay hospitals far above acquisition costs for biosimilars.

Biosimilars 80

Biosimilars Hospitals Pharmacy Production 80

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version.

Biosimilars 67

Biosimilars Pharmacy Drugs Production 67

Drug Channels

JANUARY 19, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products.

Biosimilars 95

Biosimilars Pharmacy Drugs Production 95

Drug Channels

APRIL 3, 2024

The 2024 formularies described below should boost biosimilar adoption. As a new Biosimilar Council report shows , Humira retained 99% of market share in late 2023, despite being more expensive than its biosimilars. This year, Humira and its 14 biosimilars will provide the most intriguing formulary drama.

Biosimilars 52

Biosimilars Pharmacy Drugs Production 52

Drug Channels

APRIL 20, 2022

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products.

Biosimilars 85

Biosimilars Pharmacy Drugs Production 85

Drug Channels

MARCH 5, 2024

WHAT YOU WILL LEARN In 2023, the Inflation Reduction Act of 2022 (IRA) began to alter the Medicare Part D program and trigger changes in beneficiary out-of-pocket spending, drug prices, pharmacy economics, and market access strategies. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 85

Pharmacy Biosimilars Drugs Marketing 85

Drug Channels

JANUARY 27, 2023

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment.

Biosimilars 77

Biosimilars Pharmacy Therapies Production 77

FDA Law Blog: Biosimilars

AUGUST 21, 2023

Attorney’s Office for the Western District of Texas announced that People’s Rx, a local chain operating five retail pharmacies and a compounding laboratory in the Austin area, agreed to pay $200,000 to settle allegations that it violated the Controlled Substances Act (“CSA”). 16, 2023 ( DOJ Press Release ). 2, 2020 ( DOJ Press Release ).

Pharmacy 52

Pharmacy Regulations Production Laboratories 52

Drug Channels

OCTOBER 1, 2024

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. Section V.E.

Biosimilars 40

Biosimilars Pharmacy Production FDA 40

FDA Law Blog: Biosimilars

MARCH 29, 2023

While many states have had standing orders that allow for the dispensing of naloxone without an individual prescription, “harm reduction programs” that provide products and services to at-risk individuals still faced logistical difficulties in acquiring naloxone due to its prescription-only status which I discussed in this October 2022 blog post.

Pharmacy 105

Pharmacy FDA FDA Approval Production 105

Drug Channels

OCTOBER 17, 2022

Join your colleagues from across the industry and be part of critical, solution-focused discussions designed to help optimize distribution models and channel strategies driven by market dynamics, product types, site of care and reimbursement, all delivered by an expert speaking faculty.

Biosimilars 58

Biosimilars Pharmacy Therapies Production 58

Drug Channels

OCTOBER 23, 2023

With regulation and policy changes, specifically surrounding the DCSCA, IRA and serialization, the loss of exclusivity wave, adoption of low-WAC products affecting GTN and the rise of alternative distribution models, there has never been a more important time for industry to unite. How is health policy affecting the distribution channel?

Pharmacy 62

Pharmacy Biosimilars Production Marketing 62

FDA Law Blog: Biosimilars

MAY 13, 2024

Extolling RWE, FDA has said “RWE can be leveraged to bring new products to market, evaluate the safety and effectiveness of existing products for new uses, and assess the continued performance and safety of products once on the market.”

FDA 111

FDA Production Trials Pharmacy 111

Agency IQ

OCTOBER 20, 2023

BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions This week, FDA and its grantees briefed stakeholders on the status of research projects funded through the Biosimilar User Fee Act (BSUFA III) Regulatory Science Pilot Program. Developing biosimilars is an extensive and expensive process.

Science 40

Science Biosimilars FDA Production 40

FDA Law Blog: Biosimilars

FEBRUARY 5, 2024

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Licensing 45

Licensing Licensing Pharmacy Regulations 45

FDA Law Blog: Biosimilars

MARCH 4, 2024

Livornese — On February 6, 2024, FDA issued a draft guidance titled Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act. blood supply; and, Manufacturers of certain finished drug products marketed without an approved NDA or ANDA.

FDA 59

FDA Production Marketing Drugs 59

FDA Law Blog: Biosimilars

JUNE 5, 2023

By Dara Katcher Levy — The Academy of Managed Care Pharmacy (AMCP)’s Format Executive Committee is excited to let you know that after two years of work, version 5.0 of the Format for Formulary Submissions (also known as dossiers) is on the horizon. And we need your feedback! The Format was last updated to version 4.1

Pharmacy 45

Pharmacy Production Drugs 45

FDA Law Blog: Biosimilars

JUNE 16, 2023

Prohibition on Excessive Price Increases The law prohibits manufacturers from imposing or causing to be imposed an “excessive price increase,” whether directly or through a wholesale distributor, pharmacy, or similar intermediary, on the sale of any generic or off-patent drug sold or dispensed to any consumer in the state.

Drugs 45

Drugs Biosimilars Production Treatment 45

FDA Law Blog: Biosimilars

JANUARY 22, 2024

Recalls, warning letters to online pharmacies, and drug-related import alerts were key tools for OC’s efforts to safeguard the drug supply chain from adulterated products over the prior fiscal year. Drug Supply Chain. Communication in this area included on-line videos, webinars, summits, conferences, and international outreach.

Compliance 59

Compliance Online Pharmacies Clinical Trials FDA 59

FDA Law Blog: Biosimilars

SEPTEMBER 30, 2024

CMS did not finalize the price verification survey, which would have required manufacturers of 10 costly drugs selected annually to provide clinical information as well as information on production, distribution, research, and marketing costs, revenue and profit, and ex-U.S. pricing, among other things.

Drugs 59

Drugs Regulations International Production 59

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Manufacturers must also ensure that all electronic FDA listings and all NDC listings with the electronic database vendors used to process pharmacy claims, including information about discontinued drugs, are up to date for all applicable drug and selected drug NDCs. covered insulin product or vaccine). 1395w-114c(b)(4)(B)(i).

Compliance 105

Compliance Drugs Pharmacy Licensing 105

FDA Law Blog: Biosimilars

APRIL 8, 2024

In its report, Drug Shortages: Root Causes and Potential Solutions, FDA explains that the equipment needed to produce sterile injectables is highly specialized and expensive, meaning that in a shortage situation, production capacity cannot be substantially increased without taking the time and expense of procuring and qualifying new equipment.

Drugs 59

Drugs FDA Hospitals Government 59

FDA Law Blog: Biosimilars

JULY 5, 2023

As explained in the Draft Guidance, the prohibition on wholesaling “preserves important distinctions between outsourcing facilities, which are intended to compound drugs for patients whose medical needs cannot be met by approved drugs, from conventional manufacturers, which generally engage in mass manufacturing of FDA-approved drug products.”

FDA 52

FDA FDA Approval Licensing Licensing 52

FDA Law Blog: Biosimilars

MARCH 27, 2023

In addition, the final rule requires the submission of product information to the Global Unique Device Identification Data (GUDID). This transition does not apply to Class I devices that had a Universal Product Code (UPC). Check out here and here to see if a device is classified with product codes included for these two alternatives.

Packaging 45

Packaging Compliance FDA Production 45

Agency IQ

SEPTEMBER 29, 2023

An avalanche of new legislation: Speaking of Congress, the House and Senate are back in session as of mid-September and we have already noticed a lot of legislative interest in the FDA – probably about two dozen bills related to drug shortages, generic drug competition, supply chain security, opioids, medical device recalls and orphan drug products.

FDA 40

FDA Science Regulations Production 40

FDA Law Blog: Biosimilars

JUNE 2, 2023

For 10 high-cost single source covered outpatient drugs selected annually by CMS, manufacturers would be required to respond to a so-called “price verification survey” by providing not only clinical and utilization information about the drug, but also costs of production, distribution, research, and marketing; revenue and profit; and ex-U.S.

Drugs 59

Drugs Regulations Government Vaccine 59

Agency IQ

OCTOBER 27, 2023

WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025.

FDA 40

FDA Science Regulations Production 40

Agency IQ

FEBRUARY 15, 2024

CDRH FY2024 Guidance Agenda Administrative, Procedural Enforcement Policy for In Vitro Diagnostic Product for Immediate Response to an Emerging Outbreak of an Infectious Biological Agent Prior to a Declaration under Section 564 CDRH Draft By 10/1/24 New on CDRH’s guidance agenda. Priority A List. Called for under MDUFA. Priority A List.

FDA 40

FDA Science Biosimilars Clinical Trials 40

Agency IQ

FEBRUARY 12, 2024

However, the FDA does not publish a singular guidance agenda; rather, it publishes separate agendas from each major product review center (CBER, CDER, CDRH, CFSAN), as well as some additional FDA offices (like its Office of the Chief Scientist ). This list is known as the FDA’s “guidance agenda.”

Biosimilars 40

Biosimilars Science Clinical Pharmacology FDA 40

Agency IQ

DECEMBER 1, 2023

This is what OIRA is currently reviewing. Note: If a link no longer works, it is likely because OIRA has since cleared the document.)

FDA 40

FDA Science Regulations Production 40

FDA Law Blog: Biosimilars

OCTOBER 29, 2023

This guidance was based on stakeholder feedback that the current FDA Birth Control Guide may not identify all and/or newer contraceptive products approved, cleared, or granted by FDA.

FDA Approval 45

FDA Approval FDA Production Pharmacy 45

The Pharma Data

AUGUST 21, 2020

In non-COVID-19 news, Amazon has entered the pharmaceutical market by launching ‘Amazon Pharmacy’ in India, while Johnson & Johnson is set to buy the Cambridge-based Momenta Pharmaceuticals for $6.5 Amazon Pharmacy launches in India. Amazon has entered the pharmaceutical market by launching ‘Amazon Pharmacy’ in India.

Biosimilars 52

Biosimilars Pharmacy Vaccine Pharmaceuticals 52

FDA Law Blog: Biosimilars

NOVEMBER 11, 2024

In its response to FAQs, FDA further explained that the law affected combination products and touted that “In response to the issue of misuse of pseudoephedrine-containing products, many companies are voluntarily re-formulating their products.”

FDA 111

FDA Production Pharmacy International 111

Drug Channels

NOVEMBER 12, 2024

Fein will share his latest thinking and projections on a wide range of topics, including: Latest predictions for the Inflation Reduction Act Expectations for the Medicare Part D market in 2025 and beyond Update on 340B Drug Pricing Program’s controversies Impact of the new Trump administration and Congress on the drug channel Vertical integration and (..)

Biosimilars 85

Biosimilars Drugs Pharmacy Marketing 85